The translation of these results into clinical trials remains challenging and is a matter of safety concerns: in the case of BDNF applied as a neuro-protective agent after stroke, the administration of very large quantities would be necessary as well as repeated dosing to overcome the limited amount of protein that reaches the CNS, even with transient disruption of the blood-brain barrier after stroke. The gene discussed is BDNF; the disease is Stroke.